|Bid||76.0100 x 100|
|Ask||81.6900 x 200|
|Day's Range||78.6900 - 80.8100|
|52 Week Range||31.3800 - 86.9200|
|PE Ratio (TTM)||-16.55|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Alnylam Pharmaceuticals (ALNY:Nasdaq) By Credit Suisse ($85.21, June 26, 2017) We are raising our target price on Alnylam Pharmaceuticals to $96 from $90 as we increased our probability of success from 40% to 60% in porphyria. At 100% success this adds $12 a share to our model (due to high operating leverage and modeling of fixed costs for the research platform). At 0% success to porphyria our discounted-cash-flow model is $18 a share lower at $78 a share.
How Alnylam, Puma, Immunogen, Sangamo, and Calithera beat all others to be the best biotech stocks of the year so far.
Shares of Alnylam Pharmaceuticals, Inc. (ALNY) soared 93.3% this year so far massively outperforming the 2.6% increase registered by the Zacks classified Biomed/Genetics industry during this period.